Journal of Cutaneous Immunology and Allergy | New and Recent Articles https://www.frontierspartnerships.org/journals/journal-of-cutaneous-immunology-and-allergy RSS Feed for Journal of Cutaneous Immunology and Allergy | New and Recent Articles en-us Frontiers Feed Generator,version:1 2026-09-02T11:46:10.948+00:00 60 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17320 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17320 <![CDATA[Resolution of direct antiglobulin test-negative autoimmune hemolytic anemia without corticosteroid therapy after discontinuation of nivolumab plus ipilimumab therapy for subungual melanoma]]> 2026-09-01T00:00:00Z Letter to the Editor Michiko NakajimaShintaro SaitoMizuki SatoMizuho NakajimaSahori YamazakiMasahito YasudaSei-ichiro Motegi https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17346 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17346 <![CDATA[Case Report: Successful dupilumab treatment for refractory atopic dermatitis-like eczema in a patient with Costello syndrome]]> 2026-08-31T00:00:00Z Case Report Toshihiko NonakaJun KidoMika OgataTaiga MiyakeTakanobu YoshidaSatoshi FukushimaRie SeyamaYuri UchiyamaNaomichi MatsumotoKimitoshi Nakamura T, p.(Gly13Cys), who developed severe atopic dermatitis-like eczema and hen’s egg and cow’s milk allergies from infancy. Despite treatment with topical anti-inflammatory agents and emollients, her AD-like eczema remained refractory. Add-on dupilumab therapy was initiated in adolescence, resulting in marked improvement in her skin manifestations within 1 month, and clinical improvement was maintained during subsequent follow-up. This case suggests that dupilumab may be an effective therapeutic option for refractory atopic dermatitis-like eczema associated with Costello syndrome. The clinical course also supports the possible contribution of epithelial-driven type 2 inflammation to severe allergic manifestations in Costello syndrome, although direct mechanistic evidence was not obtained.]]> https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17110 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17110 <![CDATA[Asymmetrical anhidrosis with hyperpigmentation in a patient with type 1 diabetes]]> 2026-08-28T00:00:00Z Letter to the Editor Mika FujiwaraTadatsune IidaAtsushi OdaHana TakeshitaTakeshi NamikiNaoko Okiyama https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16659 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16659 <![CDATA[Cabozantinib-associated microthrombi causing necrotizing fasciitis-like findings]]> 2026-08-27T00:00:00Z Letter to the Editor Ichiyo KawamotoYoshimi MatsuoTakumi SakamotoMichiko KishiTomofumi NumataTakanobu KanAkio Tanaka https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17229 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17229 <![CDATA[Antinuclear antibody positivity rate and clinical characteristics in prurigo chronica multiformis: a retrospective study of 26 patients]]> 2026-08-18T00:00:00Z Original Research Kyoko MuraokaYutaka InabaKoki KayamaMasatoshi Jinnin https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17025 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17025 <![CDATA[A case of Merkel cell carcinoma mimicking cellulitis during Janus kinase inhibitor therapy]]> 2026-08-13T00:00:00Z Letter to the Editor Takumi SakamotoTakanobu KanDaiki MatsubaraAkio Tanaka https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16615 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16615 <![CDATA[A case of anti-laminin 332-type mucous membrane pemphigoid with ocular symptoms successfully treated with mycophenolate mofetil and prednisolone in an elderly man]]> 2026-08-11T00:00:00Z Letter to the Editor Shoko FukumitsuTakashi HashimotoYukari MatsumotoTakayuki NagaiKeisuke IritaniYoshiaki HirakoAkiharu KuboTakeshi Fukumoto https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17140 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.17140 <![CDATA[Dissecting cellulitis of the occipital scalp with hair retention within sinus tracts]]> 2026-07-29T00:00:00Z Letter to the Editor Yuto YamamuraKazuyasu FujiiKazutoshi NishimuraShunya UsuiAtsushi Otsuka https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16999 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16999 <![CDATA[Low C1q alone should not be taken as diagnostic of acquired angioedema in a kindred with familial type 1 C1-inhibitor deficiency and overlapping systemic lupus erythematosus]]> 2026-07-07T00:00:00Z Letter to the Editor Amane TakagiSaori TakamuraTomoo Fukuda https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16781 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16781 <![CDATA[Perioperative anaphylaxis caused by rocuronium bromide: a case series of four patients with skin test confirmation]]> 2026-07-02T00:00:00Z Letter to the Editor Sayumi AraiNagisa YoshiharaRei Watanabe https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16460 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16460 <![CDATA[Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk]]> 2026-06-03T00:00:00Z Review Lai-San WongJen-Hau YangYu-Ta YenJenq-Lin Yang https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16775 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16775 <![CDATA[Remarkable effect of nivolumab on late liver metastasis recurrence in advanced malignant melanoma]]> 2026-05-29T00:00:00Z Letter to the Editor Shoka FukuizumiSoichiro KadoTakayo AndoAtsuko SatoKoji KamiyaTakeo MaekawaMamitaro OhtsukiMayumi Komine https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16442 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16442 <![CDATA[Real-world effectiveness and safety of tildrakizumab in Japanese patients with psoriasis: a single-center 52-week observational study]]> 2026-05-06T00:00:00Z Original Research Daisuke WatabeKanako TsunodaAkemi HamabataMaki GotoWakako YoshiokaHiroo Amano https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16358 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16358 <![CDATA[Deficiency of inflammatory caspases attenuates IL-33–mediated dermatitis]]> 2026-04-28T00:00:00Z Brief Research Report Mami AmakiTeruasa MurataNobuo KanazawaYasutomo Imai https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16386 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16386 <![CDATA[Immune perturbation in arsenic-induced adverse health effects and cancers]]> 2026-03-30T00:00:00Z Review Chien-Hui HongSebastian YuShu-Li WangHsin-Su YuChih-Hung Lee https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16180 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16180 <![CDATA[Case Report: A case with Xeroderma pigmentosum type F manifested a mild phenotype due to a deep intronic variant of the ERCC4 gene]]> 2026-03-20T00:00:00Z Case Report Mei TochigiYuko TakamiyaMegumi MoritaKazushi AnzawaAkira ShimizuSumihito TogiHiroki UraYo Niida A. This variant causes aberrant mRNA splicing, which confirmed the diagnosis of XP. Seven cases with the same intronic variant have been reported in Japan. In our case, we independently analyzed the qualitative and quantitative aspects of abnormal mRNA splicing, which had not been reported previously, and found approximately 7.7% of the mRNA retained normal splicing. Furthermore, immunostaining of patient’s skin with anti-ERCC4/XP antibody confirmed that the ERCC4 protein was partially expressed rather than being completely absent. This partial expression was predicted to be associated with the relatively mild phenotype observed in our patient.]]> https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.15800 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.15800 <![CDATA[The epidemiological and clinical association between primary focal hyperhidrosis and various skin disease in Japanese patients: outpatient questionnaire analysis]]> 2026-02-23T00:00:00Z Original Research Keiji KosakaAkihiko UchiyamaMai IshikawaSei-Ichiro Motegi https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16328 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16328 <![CDATA[Corrigendum: The possible effectiveness of difamilast in improving barrier dysfunction in patients with atopic dermatitis and in mouse model]]> 2026-02-20T00:00:00Z Correction Akihiko UchiyamaBayarmaa TaivanbatKeiji KosakaMai IshikawaAkihito UeharaMasatoshi ShimaokaKeiichiro RyuzakiSei-Ichiro Motegi https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16078 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16078 <![CDATA[Exacerbation of hand rash after dupilumab initiation in a child with atopic dermatitis who was able to continue treatment]]> 2026-02-05T00:00:00Z Letter to the Editor Kanoko KonoTakashi SakaiYutaka Hatano https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.15453 https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.15453 <![CDATA[Coexistence of lichenoid and psoriasiform eruptions following PD-1 blockade immunotherapy]]> 2026-01-22T00:00:00Z Letter to the Editor Tatsuya OgawaShin MatsumotoKeiji TabuchiToshifumi Nomura